J J Eertink, C N Burggraaff, M W Heymans, U Dührsen, A Hüttmann, C Schmitz, S Müller, P J Lugtenburg, S F Barrington, N G Mikhaeel, R Carr, S Czibor, T Györke, L Ceriani, E Zucca, M Hutchings, L Kostakoglu, A Loft, S Fanti, S E Wiegers, S Pieplenbosch, R Boellaard, O S Hoekstra, J M Zijlstra, H C W de Vet
Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy...
May 11, 2021: Blood Advances